BiotechTube
Guard Therapeutics

Guard Therapeutics

Sweden
guardtherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $40M

Overview

Guard Therapeutics is a clinical-stage biotech leveraging the protective protein alpha-1-microglobulin (A1M) to develop treatments for acute and chronic kidney injuries. The company's lead candidate, RMC-035, has progressed through Phase 2 studies for acute kidney injury (AKI) following major cardiovascular surgery, though recent strategic reviews suggest a potential pivot. Guard faces the critical challenges of advancing its platform with limited resources while navigating the high-risk, high-reward landscape of nephrology therapeutics.

NephrologyKidney Disease

Technology Platform

Therapeutic development based on the endogenous human protein alpha-1-microglobulin (A1M), which has antioxidant, anti-inflammatory, and heme-binding protective properties.

Funding History

3
Total raised:$40M
IPO$25M
Series A$12M
Seed$3M

Opportunities

The significant unmet medical need in acute kidney injury (AKI) presents a large potential market with no approved pharmacologic therapies.
The A1M platform's mechanism may also be applicable to chronic and rare kidney diseases, such as Alport Syndrome, offering expansion opportunities.
Successful clinical validation could enable exploration in other indications involving ischemia-reperfusion injury.

Risk Factors

High clinical development risk associated with proving efficacy in complex conditions like AKI, where many trials have failed.
Substantial financial risk as a pre-revenue company dependent on successful capital raises or partnerships, exacerbated by an ongoing strategic review.
Strategic and execution risk during a period of potential management change and pipeline reassessment.

Competitive Landscape

The AKI prevention/treatment space is highly competitive and littered with past failures, though it lacks any approved drug therapy, leaving the field open. Competitors include other biotechs developing anti-inflammatory, antioxidant, or repair-focused therapies. In chronic kidney diseases, the landscape includes large pharma and biotech companies with various mechanisms, making differentiation critical.

More companies in Sweden →